TURKU, FINLAND--(Marketwire - February 06, 2009) -
Live webcast will be available at www.biotie.com
Biotie Therapies Corp. (NASDAQ OMX Helsinki: BTH1V) announced today that Dr. Timo Veromaa, President and Chief Executive Officer, will be giving a presentation on the company’s drug development programs at the 11TH Annual BIO CEO & Investor Conference in New York City, on Monday, February 9, 2009 at 2:45 p.m. local time (20:45 p.m. Central European Time).
The audio and slide presentation will be webcasted live and can be accessed via Biotie website on www.biotie.com. The webcast will be available approximately 1 hour after the presentation ends and will remain accessible for 3 months. The BIO CEO & Investor Conference is a key event for the life sciences industry executives and members of the investment community to meet, network, and discuss the upcoming trends in the biotech industry. It is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. For more information, please visit www.ceo.bio.org
For further information: Ms. Virve Nurmi Investor relations manager Biotie Therapies Corp. tel. +358 2 274 8911, e-mail: virve.nurmi@biotie.com Biotie Therapies Corp.
Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.
The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finland and Radebeul, Germany. Shares are listed on NASDAQ OMX Helsinki Ltd.
For more information, please refer to www.biotie.com
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
